Interferon alpha 2 (alpha 2a), Recombinant, Human (Interferon alpha-2, IFN-alpha-2, IFNa2, IFNa2a, Interferon alpha-A, IFN-alphaA, IFNA, LeIF A, MGC125764, MGC125765)

Recombinant protein corresponding to 165aa of human Interferon-alpha 2a expressed in E.coli is a single, non-glycosylated, polypeptide chain.\n\nBiological Activity:\nThe specific activity as determined in a viral resistance assay using bovine kidney MDBK cells was found to be 2.7x10e8IU/mg.\n\nDimers and Aggregates:\n<1% (SDS-PAGE)\n\nProtein Content:\nProtein quantitation was carried out by two independent methods: \n1.UV spectroscopy at 280nm using the absorbency value of 0.924 as the extinctioncoefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). \n2. Analysis by RP-HPLC, using a standard solution of IFN-alpha(2a) as a Reference Standard.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I7661-74Z

Size

100ug

Form

Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to (same/more than)0.1mg/ml.

Purity

~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: (same/less than)0.1ng/ug (IEU/ug)

References

1. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 2005 Sep;12(5):473-80. 2. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice. Rom J Gastroenterol 2005 Jun;14(2):109-15. 3. Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, andomized multicenter trial. Dig Dis Sci 2005 Jun;50(6):1148-55. 4. A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel. Oncol Rep 2005 Jun;13(6):1145-52. 5. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat 2005 May;12(3):292-9. 6. Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm 2005 Feb;13(1):59-66.